MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 490 participants.
Also called NCT06543082
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 490 participants
- Sponsor
- Registry
-
NCT06543082
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT06543082. Allocation not applicable; no masking; primary purpose treatment. Start 2024-08-05 (actual); primary completion 2028-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study
- Acronym
- MACT II
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- Colchicine 0.6 mg
- Lead sponsor
- CHA University
- Collaborator
- Biotronik SE & Co. KG
Record details
- Record id
cardio:ct-nct06543082- Content hash
9ff4d6815c198969bbf864071ad72b1011c8583b82d5e04764a76b9140e51e53